The impact of presurgical magnetic resonance in early breast cancer: an observational study

The aim of this study was to evaluate the impact of presurgical breast magnetic resonance imaging (MRI) on the surgical management of selected patients with early-stage breast cancer who were candidates for BCT. The sample was built up according to the EUSOMA (European Society of Breast Cancer Specialists) recommendations enrolling women with unifocal unilateral early-stage breast carcinoma diagnosed by mammography, ultrasound (US) examination and in some cases also by histological analysis; all were scheduled for wider local excision. All eligible patients underwent presurgical breast MRI and findings were classified according to the BI-RADS system. In the presence of additional foci classified as BI-RADS 3-4, a targeted second-look US study was performed. If second-look US confirmed the presence of foci, needle biopsy was performed. Possible changes in the therapeutic approach resulting from preoperative MRI findings were decided upon by a multidisciplinary team. Outcome of histological examination of the surgical specimen and particularly analysis of tumor infiltration of the resection margins was the standard for determining the appropriateness of surgical strategy. A total of 123 patients underwent presurgical breast MRI. Additional foci were detected in 41.6% of patients, a greater local extension of the index lesion in 6.4%, whereas MRI confirmed local staging established by conventional imaging in 52%. However, 13.8% of additional foci were not confirmed by second-look and needle biopsy. More extensive surgery as a result of MRI findings was performed in 34.2%. This decision proved to be appropriate in 29.3% thus resulting in an over-treatment rate of 4.9%. Presurgical breast MRI resulted in confirmation of planned surgical strategy in 65.8% with an appropriateness rate of 54.5%. Surgical resection margins were positive for malignancy in 11.3% and repeated surgery was therefore required. Therapeutic strategy established on the basis of MRI was appropriate in 83.8% of cases. This study confirms the utility of MRI in presurgical workup of selected breast cancer patients. The results obtained suggest the importance of a sensitive tool such as MRI in the local staging of breast cancer before treatment planning.

Early-stage breast cancer; Breast magnetic resonance imaging; Presurgical staging

[1] Jatoi I., Proschan M.A.: “Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results”. Am. J. Clin. Oncol., 2005, 28, 289.

[2] Tillmann G., Orel S., Schnall M., Schultz D., Tan J., Solin L.: “Effect of breast magnetic resonance imaging on the clinical management of women with earlystage breast carcinoma”. J. Clin. Oncol., 2002, 20, 3413.

[3] Orel S., Schnall M.: “MR imaging of the breast for the detection, diagnosis and staging of breast cancer”. Radiology, 2001, 220, 13.

[4] Fischer U., Zachariae O., Baum F, Von Heyden D., Funke M., Liersch T.: “The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer”. Eur. Radiol., 2004, 14, 1725.

[5] Sardanelli F., Giuseppetti G.M., Panizza P., Bazzocchi M., Fausto A., Simonetti G. et al.; Italian Trial for Breast MR in Multifocal/Multicentric Cancer: “Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard”. AJR Am. J. Roentgenol., 2004, 183, 1149.

[6] Derloo E., Deterse J.L., Rutgers E.: “Additional breast lesions in patients eligible for breast-conserving therapy by MRI: Impact on preoperative management and potential benefit of computerized analysis”. Eur. J. Cancer, 2004, 41, 1393.

[7] Fischer U., Baum F., Luftner-Nagel S.: “Preoperative MR imaging in patients with breast cancer: preoperative staging, effects on recurrence rates, and outcome analysis”. Magn. Reson. Imaging Clin. N. Am., 2006, 14, 351.

[8] Lehman C.D., Gatsonis C., Kuhl C.K., Hendrick R.E., Pisano E.D., Hanna L. et al.; ACRIN Trial 6667 Investigators Group: “MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer”. N. Engl. J. Med., 2007, 356, 1295.

[9] Hlawatsch A., Teifke A., Schmidt M., Thelen M.: “Preoperative assessment of breast cancer: sonography versus MR imaging”. AJR Am. J. Roentgenol., 2002, 179, 1493.

[10] Berg W.A., Gutierrez L., NessAiver M.S., Carter W.B., Bhargavan M., Lewis R.S., Ioffe O.B.: “Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer”. Radiology, 2004, 233, 830.

[11] Hata T., Takahashi H., Watanabe K., Takahashi M., Taguchi K., Itoh T. et al.: “Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography”. J. Am. Coll. Surg., 2004, 199, 173.

[12] Van Goethem M., Schelfout K., Dijckmans L., Van Der Auwera J.C., Weyler J., Verslegers I. et al.: “MR mammography in the preoperative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound”. Eur. Radiol., 2004, 14, 809.

[13] Schnall M.D., Blume J., Bluemke D.A., Deangelis G.A., Debruhl N., Harms S. et al.: “MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883”. J. Surg. Oncol., 2005, 92, 32.

[14] Elshof L.E., Rutgers E.J., Deurloo E.E., Loo C.E., Wesseling J., Pengel K.E., Gilhuijs K.G.: “A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results”. Breast Cancer Res Treat., 2010, 124, 707.

[15] Abe H., Schmidt R.A., Shah R.N., Shimauchi A., Kulkarni K., Sennett C.A. et al.: “MR-directed (“Second-look”) ultrasound examination for breast lesions detected initially on MRI: MR and sonographic finding”. AJR Am. J. Roentgenol., 2010, 194, 370.

[16] Linda A., Zuiani C., Londero V., Bazzocchi M.: “Outcome of initially only magnetic resonance mammography-detected findings with and without correlate at second-look sonography: Distribution according to patient history of breast cancer and lesion size”. Breast., 2008, 17, 51.

[17] Enriquez L., Listinsky J.: “Role of MRI in breast cancer management”. Cleve Clin. J. Med., 2009, 76, 525.

[18] McCormack V.A., dos Santos Silva I.: “Breast density and parenchymal patterns as markers of breast cancer risk: a metaanalysis”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1159.

[19] Bevers T.B., Anderson B.O., Bonaccio E., Buys S., Daly M.B., Dempsey P.J. et al.: “NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis”. J. Natl. Compr. Canc. Netw., 2009, 7, 1060.

[20] Sardanelli F., Boetes C., Borisch B., Decker T., Federico M., Gilbert F.J. et al.: “Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group”. Eur. J. Cancer, 2010, 46, 1296.

[21] Schelling M., Gnirs J., Braun M., Busch R., Maurer S., Kuhn W. et al.: “Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography”. Ultrasound Obstet. Gynecol., 1997, 10, 48.

[22] Eberl M.M., Fox C.H., Edge S.B., Carter C.A., Mahoney M.C.: “BI-RADS classification for management of abnormal mammograms”. J. Am. Board Fam. Med., 2006, 19, 161.

[23] Holland R., Veling S.H., Mravunac M., Hendriks J.H.: “Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery”. Cancer, 1985, 56, 979.

[24] Liberman L., Morris E.A., Dershaw D.D., Abramson A.F., Tan L.K.: “MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer”. Am. J. Roentgenol., 2003, 180, 901.

[25] Bedrosian I., Mick R., Orel S.G., Schnall M., Reynolds C., Spitz F.R. et al.: “Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging”. Cancer, 2003, 98, 468.

[26] Liberman L., Morris E.A., Kim C.M., Kaplan J.B., Abramson A.F., Menell J.H. et al.: “MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer”. AJR, 2003, 180, 333.

[27] Schelfout K., Van Goethem M., Kersschot E., Colpaert C., Schelfhout A.M., Leyman P. et al.: “Contrast-enhanced MR imaging of breast lesions and effect on treatment”. Eur. J. Surg. Oncol., 2004, 30, 501.

[28] Sardanelli F., Bacigalupo L., Carbonaro L., Esseridou A., Giuseppetti G.M., Panizza P. et al.: “What is the sensitivity of mammography and dynamic MR imaging for DCIS if the whole-breast histopathology is used as a reference standard?”. Radiol. Med., 2008, 113, 439.

[29] Malur S., Wurdinger S., Moritz A., Michels W., Schneider A.: “Comparison of written reports of mammography, sonography and magnetic resonance mammography for preoperative evaluation of breast lesions, with special emphasis on magnetic resonance mammography”. Breast Cancer Res., 2001, 3, 55.

[30] Hlawatsch A., Teifke A., Schmidt M., Thelen M.: “Preoperative assessment of breast cancer: sonography versus MR imaging”. AJR Am. J. Roentgenol., 2002, 179, 1493.

[31] Hwang E.S., Kinkel K., Esserman L.J., Lu Y., Weidner N., Hylton N.M.: “Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity”. Ann. Surg. Oncol., 2003, 10, 381.

[32] Kristoffersen Wiberg M., Aspelin P., Sylvan M., Boné B.: “Comparison of lesion size estimated by dynamic MR imaging, mammography and histopathology in breast neoplasms”. Eur. Radiol., 2003, 13, 1207.

[33] Kriege M., Brekelmans C.T., Boetes C., Besnard P.E., Zonderland H.M., Obdeijn I.M. et al.: “Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition”. N. Engl. J. Med., 2004, 351, 427.

[34] Leach M.O., Boggis C.R., Dixon A.K., Easton D.F., Eeles R.A., Evans D.G. et al.: “Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)”. Lancet, 2005, 365, 1769.

[35] Kuhl C.K., Schrading S., Leutner C.C., Morakkabati-Spitz N., Wardelmann E., Fimmers R. et al.: “Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer”. J. Clin. Oncol., 2005, 23, 8469.

[36] Houssami N., Hayes D.F.: “Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breastcancer?”. Cancer J. Clin., 2009, 59, 290.

[37] Godinez J., Gombos E.C., Chikarmane S.A., Griffin G.K., Birdwell R.L.: “Breast MRI in the evaluation of eligibility for accelerated partial breast irradiation”. AJR Am. J. Roentgenol., 2008, 191, 272.

[38] Heywang-Köbrunner S.H., Bick U., Bradley W.G. Jr., Boné B., Casselman J., Coulthard A. et al.: “International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions”. Eur. Radiol., 2001, 11, 531.

[39] Neubauer H., Li M., Kuehne-Heid R., Schneider A., Kaiser W.A.: “High grade and nonhigh grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement”. Br. J. Radiol., 2003, 76, 3.

[40] Menell J.H., Morris E.A., Dershaw D.D., Abramson A.F., Brogi E., Liberman L.: “Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging”. Breast J., 2005, 11, 382.

[41] Kuhl C.K., Schrading S., Bieling H.B., Wardelmann E., Leutner C.C., Koening R. et al.: “MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study”. Lancet, 2007, 370, 485.

[42] Mann R.M., Loo C.E., Wobbes T., Bult P., Barentsz J.O., Gilhuijs K.G., Boetes C.: “The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast”. Breast Cancer Res. Treat., 2010, 119, 415.

[43] Brix G., Henze M., Knopp M.V., Lucht R., Doll J., Junkermann H. et al.: “Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience”. Eur. Radiol., 2001, 11, 2058.

[44] Bluemke D.A., Gatsonis C.A., Chen M.H., DeAngelis G.A., DeBruhl N., Harms S. et al.: “Magnetic resonance imaging of the breast prior to biopsy”. JAMA, 2004, 292, 2735.

[45] Peters N.H., Borel Rinkes I.H., Zuithoff N.P., Mali W.P., Moons K.G., Peeters P.H.: “Meta-Analysis of MR Imaging in the diagnosis of breast lesions”. Radiology, 2008, 246, 116.

[46] Warren R., Ciatto S., Macaskill P., Black R., Houssami N.: “Technical aspects of breast MRI-do they affect outcomes?”. Eur. Radiol., 2009, 19, 1629.

[47] Pettit K., Swatske M.E., Gao F., Salavaggione L., Gillanders W.E., Aft R.L. et al.: “The impact of breast MRI on surgical decisionmaking: are patients at risk for mastectomy?”. J. Surg. Oncol., 2009, 100, 553.